Treating BRCA-mutant breast cancers with PARP inhibitors improved patient outcome,51 so PARP inhibitors may also show increased effectiveness in bladder tumors with BRCA2 or other FA mutations. This evidence concerns the gene BRCA2 and breast cancer.